» Articles » PMID: 36821034

Analyzing the Impact of FSHR Variants on Polycystic Ovary Syndrome-a Case-Control Study in Punjab

Overview
Journal Reprod Sci
Publisher Springer
Date 2023 Feb 23
PMID 36821034
Authors
Affiliations
Soon will be listed here.
Abstract

Polycystic ovary syndrome (PCOS) is an endocrine-metabolic syndrome that involves hyperandrogenism, menstrual irregularities, and/or small cysts in one or both ovaries which might lead to infertility in women. The genetics of PCOS is heterogenous with the involvement of several genes reported in the hypothalamic-pituitary-gonadal axis. Follicular growth and steroidogenesis regulation are both critically dependent on follicle-stimulating hormone (FSH). The variants of FSHR cause abnormal folliculogenesis, steroidogenesis, and oocyte maturation at various stages of growth and may render women more susceptible to PCOS development. The present case-control study evaluated the association of FSHR rs6165 and rs6166 variants with PCOS. A total of 743 females were recruited. PCR-RFLP method was used for the genotypic analysis of FSHR polymorphisms. Obesity was examined according to the categorization of body mass index (BMI) and waist-hip ratio (WHR). Biochemical analysis, including a lipid profile, LH, FSH, and testosterone levels, was done in both PCOS women and controls. BMI and WHR revealed a statistically significant difference between PCOS cases and controls. Overall, levels of HDL were significantly lower, whereas cholesterol, triglycerides, LDL, and VLDL levels were higher in PCOS women (p < 0.05). The genotypic and allelic frequencies of rs6165 and rs6166 did not demonstrate significant differences when PCOS women were compared with the control group. However, clinical features of PCOS including gonadotropic hormone (FSH), hyperandrogenism, and dyslipidemia were significantly correlated with variants of FSHR. The present study concludes that rs6165 and rs6166 were significantly related to clinical features of PCOS, regardless of providing direct disease risk.

Citing Articles

Structural changes in amide I and amide II regions of PCOS women analyzed by ATR-FTIR spectroscopy.

Kaur M, Singh S, Kaur A Heliyon. 2024; 10(13):e33494.

PMID: 39040335 PMC: 11261041. DOI: 10.1016/j.heliyon.2024.e33494.


Application of Biomarkers in Obese Infertile Women: A Genetic Tool for a Personalized Treatment.

Voros C, Bananis K, Papapanagiotou A, Pouliakis A, Mavriki K, Gkaniatsos I J Clin Med. 2024; 13(8).

PMID: 38673534 PMC: 11051271. DOI: 10.3390/jcm13082261.


Significance of LHCGR polymorphisms in polycystic ovary syndrome: an association study.

Singh S, Kaur M, Beri A, Kaur A Sci Rep. 2023; 13(1):22841.

PMID: 38129424 PMC: 10739822. DOI: 10.1038/s41598-023-48881-0.


Polymorphisms in FSHR modulating susceptibility to polycystic ovary syndrome: an updated meta-analysis.

Kaur M, Singh S, Kaur A J Ovarian Res. 2023; 16(1):183.

PMID: 37653412 PMC: 10472705. DOI: 10.1186/s13048-023-01238-7.


Molecular Role of Asn680Ser and Asp37Glu Missense Variants in Saudi Women with Female Infertility and Polycystic Ovarian Syndrome.

Alshammary A, Alsobaie S, Alageel A, Aldakheel F, Ansar S, Alrashoudi R Curr Issues Mol Biol. 2023; 45(7):5494-5514.

PMID: 37504264 PMC: 10378235. DOI: 10.3390/cimb45070348.

References
1.
Vishnubotla D, Shek A, Madireddi S . Pooled genetic analysis identifies variants that confer enhanced susceptibility to PCOS in Indian ethnicity. Gene. 2020; 752:144760. DOI: 10.1016/j.gene.2020.144760. View

2.
Ndefo U, Eaton A, Green M . Polycystic ovary syndrome: a review of treatment options with a focus on pharmacological approaches. P T. 2013; 38(6):336-55. PMC: 3737989. View

3.
Goodarzi M, Dumesic D, Chazenbalk G, Azziz R . Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011; 7(4):219-31. DOI: 10.1038/nrendo.2010.217. View

4.
Dumesic D, Oberfield S, Stener-Victorin E, Marshall J, Laven J, Legro R . Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome. Endocr Rev. 2015; 36(5):487-525. PMC: 4591526. DOI: 10.1210/er.2015-1018. View

5.
Singh A, Bora P, Krishna A . Systemic adiponectin treatment reverses polycystic ovary syndrome-like features in an animal model. Reprod Fertil Dev. 2017; 30(4):571-584. DOI: 10.1071/RD17255. View